SAN JOSE, Calif., July 20, 2020 /PRNewswire/ -- Anixa Biosciences,
Inc. (NASDAQ: ANIX), a biotechnology company focused on the
treatment and prevention of cancer and infectious diseases, today
announced that due to public health and safety concerns related to
the ongoing COVID-19 global pandemic and to support the health and
well-being of its stockholders, employees and others, the Company
is changing its 2020 Annual Meeting of Stockholders (the "Annual
Meeting") to a virtual-only format that will be held via live audio
webcast.
As previously announced, the Annual Meeting will be held on
August 13, 2020 at 10:00 a.m. Pacific Time, but will be held via
live audio webcast. Any shareholders that wish to
participate, vote and ask questions at the virtual Annual Meeting
should log in at www.virtualshareholdermeeting.com/ANIX2020 and
then enter the control number found on their proxy card, voting
instruction or notice previously received. Further
information regarding this change to a virtual Annual Meeting can
be found in the supplemental proxy materials filed by Anixa with
the Securities and Exchange Commission on July 20, 2020.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutic portfolio includes a cancer immunotherapy program which
uses a novel type of CAR-T, known as chimeric endocrine receptor
T-cell (CER-T) technology, and a Covid-19 therapeutics program
focused on inhibiting certain viral protein function. The
company's vaccine portfolio consists of a technology focused on the
immunization against α-Lactalbumin to prevent triple negative
breast cancer (TNBC). Anixa continually examines emerging
technologies in complementary fields for further development and
commercialization. Additional information is available at
www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-change-to-virtual-format-for-2020-annual-meeting-of-stockholders-301095802.html
SOURCE Anixa Biosciences, Inc.